Much Cheaper PrEP Drugs Could Mean Financial Upheaval for 340B Covered Entities
While an important drug’s introduction into the generic market is often celebrated by both providers and patients, generic pre-exposure prophylaxis drugs (PrEP) for patients at risk of contracting HIV could prove a financial disaster for some 340B covered entities.